FDA Approves INVOKANA (canagliflozin) to Reduce the Risk of CV Events
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved INVOKANA (canagliflozin) to reduce the risk of…
Read More...
Read More...
